AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baquero, M.-R.
Right arrow Articles by Baquero, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baquero, M.-R.
Right arrow Articles by Baquero, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2005, p. 4754-4756, Vol. 49, No. 11
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.11.4754-4756.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Increased Mutation Frequencies in Escherichia coli Isolates Harboring Extended-Spectrum ß-Lactamases

María-Rosario Baquero, Juan Carlos Galán, María del Carmen Turrientes, Rafael Cantón, Teresa M. Coque, José Luis Martínez, and Fernando Baquero*

Department of Microbiology, Ramón y Cajal University Hospital, and Centro Nacional de Biotecnología (CSIC-RYC Associated Unit on Antibiotic Resistance and Bacterial Virulence), 28034 Madrid, Spain

Received 27 April 2005/ Returned for modification 6 July 2005/ Accepted 16 August 2005


   ABSTRACT
Top
 Abstract
Text
 References
 
Hypermutable (mutation frequency [f], ≥4 x 10–8) Escherichia coli strains were more frequently found (43%) in a collection of 89 extended-spectrum ß-lactamase (ESBL)-producing isolates from different patients (77 pulsed-field gel electrophoresis clones, 12 ESBL types) than in non-ESBL E. coli (26%) strains (P = 0.03). Among urinary tract isolates, the frequency of hypermutation was 40% in ESBL versus 26% in non-ESBL isolates (P = 0.03).


   TEXT
Top
 Abstract
 Text
References
 
Since the early 1980s, several extended-spectrum beta-lactamases (ESBLs) have emerged in Escherichia coli strains, probably as a consequence of the use of broad-spectrum antibiotics (24). Classic ESBLs have evolved from plasmid genes encoding the previous broad-spectrum beta-lactamases (6), such as TEM-1, TEM-2, or SHV-1, by mutation in one to six positions in their sequences (http://www.lahey.org/studies). More recently, CTX-M-type ESBL genes have emerged in enterobacterial organisms by capture of chromosomal sequences of environmental bacteria and have undergone further genetic divergence by mutational and possibly recombinational events (5, 21). The sequential acquisition of mutations in ESBL genes is probably due to a stepwise process involving successive rounds of selection (19). Bacterial mutation rates might be variable (16). The modal frequency of mutation in E. coli strains originating either from clinical specimens or from fecal samples of healthy volunteers is, as expected (10), a constant value (1 x 10–8), but a consistent number of isolates present increased frequencies of mutation (f) (2). Most of these isolates are considered weak mutators, with mutation frequencies ranging from 4 x 10–8 to 4 x 10–7. Since mutator phenotypes increase both the rate of mutation and the rate of homeologous recombination (4, 7, 26), it is conceivable that the emergence and dissemination of ESBLs could be facilitated in E. coli strains with increased frequencies of mutation. In fact, mutator strains have been used to predict the emergence of ESBLs under laboratory conditions (11, 22).

In order to examine this hypothesis, we studied a highly diverse collection of 89 E. coli strains (only 1 isolate per patient; 77 different pulsed-field gel electrophoresis clones) harboring 12 different ESBL types. The ESBL distribution was as follows: 18 TEM-4 strains, 2 TEM-12 strains, 2 TEM-24 strains, 1 SHV-1 strain, 5 SHV-2 strains, 1 SHV-5 strain, 7 SHV-12 strains, 2 SHV-13 strains, 5 CTX-M-1 strains, 31 CTX-M-9 strains, 9 CTX-M-10 strains, and 6 CTX-M-14 strains. The strains were isolated at our hospital from 1988 to 2002. Pulsed-field gel electrophoresis was carried out and analyzed as previously described (8, 25). ESBLs were characterized by isoelectric focusing, amplification of bla genes by PCR using primers and conditions previously described, and further sequencing of PCR products (8). The mutation frequencies of these strains were obtained by determining the proportion of rifampin-resistant colonies per total viable cell count (2). Results are means from at least three independent experiments for each strain. The technique was previously validated using classic Luria-Delbrück determinations (2)

The distribution of rifampin resistance mutation frequencies of the 89 E. coli strains harboring ESBLs is shown in Fig. 1. According to the categories previously described by our group (2), 2% of the strains were hypomutable (f ≤ 8 x 10–9), 55% were normomutable (8 x 10–9 < f < 4 x 10–8), and 43% were hypermutable (weak mutators; 4 x 10–8 ≤ f < 4 x 10–7). We could not find any strong mutators (f ≥ 4 x 10–7) in our ESBL-producing E. coli collection. The overall proportion of ESBL-producing strains with increased mutation frequencies was found to be the highest ever described after studying many different E. coli strains of different geographical and clinical origins (2, 14, 15). Indeed, the proportion of hypermutable strains was the highest (43%) compared with different collections (100 strains each) of E. coli from blood cultures (39%), urine cultures (26%), or feces from human volunteers (12%) studied in the same hospital (Fig. 1). Most of our ESBL-producing isolates (56%) were recovered from urinary tract infections. Uropathogenic E. coli strains had been shown to have a high frequency of mutators compared with isolates from commensal bacteria (2, 9, 18). We compared the observed mutation frequencies in the subset of ESBL-producing urinary isolates with those of the non-ESBL collection of strains from positive urine cultures recovered in our hospital (Fig. 2). It is noteworthy that 40% of urinary ESBL-positive E. coli strains had increased mutation rates, whereas the percentage of mutators among ESBL-negative isolates was just 26% (P = 0.03). The mutation frequencies found for the different ESBL groups in our series are presented in Fig. 3. The highest percentage of hypermutation was found for strains carrying TEM derivatives (50%), whereas enzymes of the CTX-M-9 group (CTX-M-9 and CTX-M-14) were harbored by a group of strains with a lower proportion of hypermutators (38%). Probably due to low numbers, these differences did not reach statistical significance.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 1. Distribution of rifampin mutation frequencies of 100 E. coli isolates from: stools of healthy volunteers (white), 100 E. coli isolates from urinary tract infections (light gray), 100 E. coli isolates from blood (dark gray), and 89 E. coli strains harboring ESBLs (black). Categories: hypomutable (f ≤ 8 x 10–9), normomutable (8 x 10–9 < f < 4 x 10–8), weakly hypermutable (4 x 10–8 ≤ f < 4 x 10–7), and strongly hypermutable (f ≥ 4 x 10–7).

 


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 2. Comparison of distributions (expressed as percentages) of mutation frequencies of 100 uropathogenic E. coli isolates without ESBLs (black) and 50 uropathogenic E. coli isolates with ESBLs (gray). Categories are explained in the legend to Fig. 1.

 


View larger version (18K):
[in this window]
[in a new window]
  		FIG. 3. Frequencies of mutation of strains containing different types of ESBLs. The statistical significance (P) of the difference between TEM-type ESBLs and non-ESBLs was 0.072.

 
To investigate the possibility that hypermutable strains could eventually be better recipients of ESBL-encoding plasmids, we analyzed the frequency of transconjugants in otherwise isogenic hypermutable and wild-type normomutable strains. We introduced by conjugation four ESBL-encoding plasmids—two from E. coli, pEC36 (TEM-4) and pEC16 (CTX-M-10), and two from Klebsiella pneumoniae, pRYCE11 (TEM-4) and pRYCE11.1 (TEM-4) (8)—into the nalidixic acid-resistant E. coli K-12 BM21 recipient strain (1). The resulting E. coli BM21 transconjugant strains harboring the ESBL plasmids listed above were then used as donors in further conjugation experiments. The recipients of these mating experiments were rifampin-resistant mutants of the normomutable strain E. coli MI1443 ({Delta}frdABCD {Delta}ampC recA Smr) and its isogenic hypermutable derivative GB20 (MI1443 mutS215::Tn10) (11). Transconjugants were selected onto LB plates containing rifampin (100 µg/ml) and cefotaxime (1 µg/ml). Three replicate experiments were run in parallel. Our results did not support the possibility that mutator strains could be better recipients of ESBL-encoding plasmids, since the frequency of conjugation per donor strain was not significantly different when the normomutable or the hypermutable strain was used as the recipient strain (data not shown). Another possibility to explain the high prevalence of hypermutable ESBL-producing strains could be a putative mutagenic effect on the recipient cell derived from the ESBL plasmid acquisition. In fact, this explanation has been suggested previously for E. coli and K. pneumoniae (3, 13). Again, such a hypothesis was not supported by our results. The mutation frequencies of E. coli K-12 BM21 strains obtained before and after mating experiments with all ESBL-encoding plasmids tested were found not to be significantly different (data not shown).

A possible scenario is that the stepwise emergence of mutations in the ESBL ancestor genes (such as those encoding TEM-1 or SHV-1, ancestors of TEM-4 and SHV-12, respectively) might have preferentially, but not necessarily, occurred in plasmids harbored by hypermutable strains, followed by plasmid transfer, eventually to other, nonhypermutable strains. However, bacterial stress associated with epidemic spread of ESBL clones in the hospital might have favored hypermutable variants. Additionally, local horizontal transfer to neighbor hospital strains (where hypermutation is more frequent) may enrich the frequency of hypermutators with ESBLs. Since hypermutable strains are more resistant to antibiotics (20), the association of ESBL production with hypermutation may have been favored by the local intensity of antibiotic selection. Indeed, hypermutable ESBL-producing strains could have been enriched by the use of fluoroquinolones, because of the easier emergence of fluoroquinolone resistance mutations (12, 23). In these hypermutable strains, and under appropriate selection, the emergence of mutations and recombinations leading to ESBLs could have been favored.

The results of our study suggest that in our hospital the presence of ESBLs is associated with a hypermutable phenotype in E. coli. Thus, the isolates harboring these enzymes might have an enhanced capacity for further adaptations to exposure to novel antibiotics or for acquisition of novel traits, allowing them to develop more-efficient mechanisms eventually increasing their epidemicity and virulence (17).


   ACKNOWLEDGMENTS
 
This work was supported by grant QLK2-CT-2001-873 from the European Commission. ESBL characterization was performed with grants from Fondo de Investigaciones Sanitarias, Ministerio de Sanidad of Spain (PI-020943), Ministerio de Ciencia y Tecnología of Spain (SAF 2003-09285), and the European Commission (LSHM-CT-2003-503335).


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Ramón y Cajal University Hospital, Ctra. de Colmenar, Km 9,1, 28034 Madrid, Spain. Phone: 34-91-3368330. Fax: 34-91-3368809. E-mail: fbaquero.hrc{at}salud.madrid.org. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Baquero, F., D. Bouanchaud, M. C. Martínez-Pérez, and C. Fernández. 1978. Microcin plasmids: a group of extrachromosomal elements coding for low-molecular-weight antibiotics in Escherichia coli. J. Bacteriol. 135:342-347.[Abstract/Free Full Text]
  2. Baquero, M. R., A. I. Nilsson, M. C. Turrientes, D. Sandvang, J. C. Galán, J. L. Martínez, N. Frimodt-Moller, F. Baquero, and D. I. Andersson. 2004. Polymorphic mutation frequencies in Escherichia coli: emergence of weak mutators in clinical isolates. J. Bacteriol. 186:5538-5542.[Abstract/Free Full Text]
  3. Bastarrachea, F. 1998. On the origin of plasmid-borne, extended-spectrum, antibiotic resistance mutations in bacteria. J. Theor. Biol. 190:379-387.[CrossRef][Medline]
  4. Blázquez, J. 2003. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. 37:1201-1209.[CrossRef][Medline]
  5. Bonnet, R. 2004. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14.[Free Full Text]
  6. Bradford, P. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.[Abstract/Free Full Text]
  7. Chopra, I., A. J. O'Neill, and K. Miller. 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6:137-145.[CrossRef][Medline]
  8. Coque, T. M., A. Oliver, J. C. Perez-Diaz, F. Baquero, and R. Cantón. 2002. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob. Agents Chemother. 46:500-510.[Abstract/Free Full Text]
  9. Denamur, E., S. Bonacorsi, A. Giraud, P. Duriez, F. Hilali, C. Amorin, E. Bingen, A. Andremont, B. Picard, F. Taddei, and I. Matic. 2002. High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J. Bacteriol. 184:605-609.[Abstract/Free Full Text]
  10. Drake, J. W. 1991. A constant rate of spontaneous mutation in DNA-based microbes. Proc. Natl. Acad. Sci. USA 88:7160-7164.[Abstract/Free Full Text]
  11. Galán, J. C., M. I. Morosini, M. R. Baquero, M. Reig, and F. Baquero. 2003. Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic {Delta}ampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor. Antimicrob. Agents Chemother. 47:2551-2557.[Abstract/Free Full Text]
  12. Giraud, A., M. Fons, and F. Taddei. 2003. Impact of mutation rate on the adaptation of gut bacteria. J. Soc. Biol. 197:389-396.[Medline]
  13. Jacoby, G. A., and L. Sutton. 1991. Properties of plasmids responsible for production of extended spectrum ß-lactamases. Antimicrob. Agents Chemother. 35:164-169.[Abstract/Free Full Text]
  14. LeClerc, J. E., B. Li, W. L. Payne, and T. A. Cebula. 1996. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274:1208-1211.[Abstract/Free Full Text]
  15. Matic, I., M. Radman, F. Taddei, B. Picard, C. Doit, E. Bingen, E. Denamur, and J. Elion. 1997. Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science 277:1833-1834.[Free Full Text]
  16. Martínez, J. L., and F. Baquero. 2000. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44:1771-1777.[Free Full Text]
  17. Martínez, J. L., and F. Baquero. 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647-679.[Abstract/Free Full Text]
  18. Miller, K., A. J. O'Neill, and I. Chopra. 2004. Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections. Antimicrob. Agents Chemother. 48:23-29.[Abstract/Free Full Text]
  19. Negri, M. C., M. Lipsitch, J. Blázquez, B. R. Levin, and F. Baquero. 2000. Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob. Agents Chemother. 44:2485-2491.[Abstract/Free Full Text]
  20. Oliver, A., R. Cantón, P. Campo, F. Baquero, and J. Blázquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.[Abstract/Free Full Text]
  21. Oliver, A., T. M. Coque, D. Alonso, A. Valverde, F. Baquero, and R. Cantón. 2005. CTX-M-10 linked to a phage-related element is widely disseminated among Enterobacteriaceae in an Spanish hospital. Antimicrob. Agents Chemother. 49:1567-1571.[Abstract/Free Full Text]
  22. Orencia, M. C., J. S. Yoon, J. E. Ness, W. P. Stemmer, and R. C. Stevens. 2001. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. 8:238-242.[CrossRef][Medline]
  23. Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, S. Mohapatra, G. M. Trenholme, K. P. Klugman, J. G. McCormack, and V. L. Yu. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30:473-478.[CrossRef][Medline]
  24. Shah, A. A., F. Hasan, S. Ahmed, and A. Hameed. 2004. Extended-spectrum beta-lactamases (ESBLs): characterization, epidemiology and detection. Crit. Rev. Microbiol. 30:25-32.[CrossRef][Medline]
  25. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
  26. Townsend, J. P., K. M. Nielsen, D. S. Fisher, and D. L. Hartl. 2003. Horizontal acquisition of divergent chromosomal DNA in bacteria: effects of mutator phenotypes. Genetics 164:13-21. (Erratum, 164:1241.)[Free Full Text]

Antimicrobial Agents and Chemotherapy, November 2005, p. 4754-4756, Vol. 49, No. 11
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.11.4754-4756.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baquero, M.-R.
Right arrow Articles by Baquero, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baquero, M.-R.
Right arrow Articles by Baquero, F.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS